Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588595 · ClinicalTrials.gov registry record · Phase 4
The Switching Antiplatelet-9 (SWAP-9) Study
A Phase 4 study of Coronary Arterial Disease (CAD), sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06588595: Recruiting Phase 4 study of Coronary Arterial Disease (CAD), sponsored by University of Florida.
NCT06588595 is a Phase 4 study of Coronary Arterial Disease (CAD) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 90 participants, below the 3,061-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588595, a Phase 4 study of Coronary Arterial Disease (CAD), is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
Primary Outcome
Comparison of PRU determined by VerifyNow between ABCD-GENE-guided de-escalation vs. unguided de-escalation.
Conditions Studied
Interventions
- DRUG Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel
- DRUG Aspirin plus clopidogrel
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 4 |
What NCT06588595 shows while recruiting
NCT06588595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 3,061-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Coronary Arterial Disease (CAD) appearing as the primary indexed condition, and to 2 interventions - of which Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel is the first listed.
NCT06588595 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06588595 about?
NCT06588595 is a clinical study titled "The Switching Antiplatelet-9 (SWAP-9) Study". The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
What is the current status of trial NCT06588595?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2024-11-01. Estimated completion is 2027-02-28.
What conditions does trial NCT06588595 study?
This clinical trial studies the following conditions: Coronary Arterial Disease (CAD).
What interventions are being tested in trial NCT06588595?
The interventions under investigation include: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel (DRUG), Aspirin plus clopidogrel (DRUG).
Who is sponsoring clinical trial NCT06588595?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588595 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Arterial Disease (CAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
RECRUITING · Phase 4
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
FORWARD CAD IDE Study
RECRUITING · NA
-
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
RECRUITING · NA
-
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI